This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Accelr8 Announces Renewal And Expansion Of SCHOTT Microarray License, And Notice Of Allowance For New Patent

Stocks in this article: AXK

Accelr8 Technology Corporation (NYSE Amex: AXK) announced that Accelr8 and SCHOTT Technical Glass Solutions, GmbH (Jena, Germany) have renewed Accelr8’s license to SCHOTT for Nexterion® microarraying slides using OptiChem® biocoatings. In addition to renewing the existing non-exclusive license, Accelr8 also granted to SCHOTT the right to sell OptiChem®-coated products for application in medical diagnostics. Previously, SCHOTT’s license excluded medical diagnostic applications. The new right for diagnostic products allows SCHOTT to sell up to 20,000 units/year to any single customer. If the customer plans to exceed this volume, SCHOTT will refer the customer to Accelr8 to negotiate a direct license from Accelr8.

In return for the license, SCHOTT paid $150,000 to Accelr8 for a license fee and non-recourse pre-paid royalties. After reaching cumulative sales that generate the prepaid royalty amount, SCHOTT will pay additional cash royalties to Accelr8 for subsequent sales. The term for the renewed license continues through November 24, 2014.

The new SCHOTT licensing rights join Accelr8’s previous direct license to Nanosphere (NASDAQ: NSPH) in medical diagnostics.

Accelr8’s Web site includes OptiChem® information and links to SCHOTT Nexterion’s® microarraying product Web site—

Accelr8 also announced receipt of a Notice of Allowance from the US Patent Office for broadened protection of methods used in Accelr8’s BACcel™ culture-free, same-day pathogen diagnostic system. Previously issued patents include system protection in the US and international markets.

According to David Howson, Accelr8’s president, “we are pleased with Schott’s decision to renew and expand its OptiChem® license in microarraying products. We believe that Schott’s global marketing reach can help capture new opportunities in the microarraying market segment.”

“The new US patent expands our protection of fundamental methods unique to our BACcel™ system. We believe that the new claims that join our growing patent estate confer protection over basic analytical principles, without limiting protection to a specific narrow method of applying them. In our opinion, this issuance significantly strengthens our intellectual property assets,” Howson concluded.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs